Human Skin Fibroblast Collagenase Inhibitor

COMPARATIVE STUDIES IN HUMAN CONNECTIVE TISSUES, SERUM, AND AMNIOTIC FLUID*

(Received for publication, April 18, 1983)

Howard G. Welgus and George P. Stricklin
From the Division of Dermatology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

In order to gain insight into the biological significance of a collagenase inhibitor secreted by human skin fibroblasts, we examined various human connective tissues and body fluids for such a protein. The inhibitors found in these tissues were compared immunologically to skin fibroblast inhibitor by Ouchterlony analysis and by the development of a highly specific enzyme-linked immunosorbent assay (ELISA). Using this ELISA, cell cultures of human skin fibroblasts, corneal fibroblasts, gingival fibroblasts, and adult and fetal lung fibroblasts secreted similar amounts of immunoreactive inhibitor protein. Each culture medium displayed a reaction of immunologic identity with skin fibroblast inhibitor when examined in Ouchterlony gel diffusion. In testing for functional inhibitory activity, the same 1:1 stoichiometry of collagenase inhibition was observed in each culture medium that characterizes the human skin inhibitor. Other mesodermally derived human cell types, including human fetal osteoblasts, uterine smooth muscle cells, fibrosarcoma cells, and explants of tendon and articular cartilage behaved in the same manner as the fibroblast cultures.

Because collagenase inhibitors with biochemical similarities to skin fibroblast inhibitor have been described in serum and in amniotic fluid, we also examined these sources of inhibitory proteins. The data indicate that both serum and amniotic fluid contain collagenase inhibitors which are immunologically and functionally identical with the skin fibroblast inhibitor. The concentration of inhibitor in serum, as measured by ELISA assay, is $1.03 \pm 0.27 \mu g/ml$.

The results suggest that collagenase inhibitors which are functionally equivalent and immunologically identical with human skin fibroblast collagenase inhibitor are synthesized by many, if not all, fetal and adult mesodermal tissues in the human organism. The inhibitor apparently gains access to certain body fluids such as serum and amniotic fluid. This inhibitor protein may, therefore, function in the regulation of collagen degradation in most human connective tissues.

Since the vertebrate collagenases initiate the specific degradation of native collagen (1, 2), the activity of these enzymes is critical to the maintenance and turnover of connective tissues. In normal tissue remodeling, collagen degradation requires precise regulation while, in certain pathologic states, elevated levels of collagenase have been associated with excessive tissue destruction (3-5).

Modulation of collagenolytic activity may also occur through the intervention of naturally occurring collagenase inhibitors which have been identified in both serum and connective tissues. Human serum is a potent inhibitor of collagenase (6); $\alpha_2$-macroglobulin, a nonspecific antiprotease, accounts for more than 95% of this inhibitory activity (7). $\alpha_2$-Macroglobulin inhibits all vertebrate collagenses investigated to date, but its large size (780,000 D), lack of specificity, and irreversible mechanism of inhibition (8) probably confine its role to the inactivation of protease that has gained access into the bloodstream, rather than to the regulation of collagenolysis within the interstices of an organized connective tissue. Tissue-derived inhibitors of collagenase, on the other hand, are more likely to be of biologic significance in the control of collagen degradation in the extracellular milieu. Using either cell or explant culture techniques, such inhibitors have been identified in several tissues including skin (9, 10), tendon (11), bone (12, 13), uterus (13), and aorta (14, 15) from various animal species. These inhibitors may constitute a distinct biologic class of compounds since they appear to share certain common features: all are glycoproteins of $M_r \sim 25,000-30,000$, they are very stable to changes in temperature and pH, and they specifically inhibit connective tissue metalloproteases. Interestingly, a $\beta_1$-serum protein (7, 16) and a glycoprotein in amniotic fluid (17, 18) have also been identified which display the same properties as the tissue inhibitors.

Another class of biologically active collagenase inhibitors appears to be cationic proteins of $M_r \sim 10,000$ which have been reported from cartilage (19, 20), aorta (19), teeth (21), and would also include platelet factor 4 (22). The cartilage-derived collagenase inhibitor may be related to substances extracted from this tissue which inhibit tumor-induced vascular proliferation (23) and bone resorption in vitro (24).

Human skin fibroblasts in monolayer culture synthesize both procollagenase (5, 25, 26) and a specific inhibitor of the active form of this enzyme (9, 10). The inhibitor is a glycoprotein of $M_r = 28,500$ that inhibits collagenase on a 1:1 stoichiometric basis (10, 27). The preceding paper describes the purification to homogeneity of human skin fibroblast collagenase inhibitor as well as its biochemical characterization and the development of a monospecific antibody (27). In this report, we demonstrate the immunologic and functional identity of the skin fibroblast inhibitor with collagenase inhibitors elaborated by human cell cultures of lung fibroblasts, corneal fibroblasts, gingival fibroblasts, fibrosarcoma cells, uterine smooth muscle cells, osteoblasts, tendon, and cartilage explants, and suggest that fibroblast collagenase inhibitor is important in the regulation of collagenolysis in most human tissues. Furthermore, the presence of this inhibitor in certain human body fluids, such as serum and amniotic fluid, is also documented.

* This work was supported by United States Public Health Service Grants AM 31078, AM 31430, RR 05389, and AM 12129, and by American Cancer Society Institutional Grant IN-36. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
**EXPERIMENTAL PROCEDURES**

**Materials**—Polystyrene microtitration plates (“U” bottom) were purchased from Dynatech. Goat anti-rabbit IgG conjugated to alkaline phosphatase and p-nitrophenyl phosphate (disodium) were obtained from Boehringer Mannheim. Solutions of the solutions in microtitration plates were measured at 405 nm with an MR 580 Dynatech spectrophotometer.

PBS-Tween-BSA, phosphate-buffered saline-Tween, and 10% diethanolamine buffer were prepared according to Voller et al. (28).

Borate buffer was prepared as described by Kearney et al. (29).

**Human Sera**—10-ml venipuncture samples were obtained from seven healthy volunteers, ages 27–29. The specimens were allowed to clot overnight; the serum was removed and then centrifuged at 2000 X g for 20 min, followed by storage at −20 °C.

**Human Amniotic Fluid**—Samples of human amniotic fluid were obtained from women undergoing repeat cesarean section who were at least at 36 weeks of gestation. All samples were free of blood and were centrifuged at 10,000 X g for 10 min prior to storage at −20 °C.

**Urine Specimens**—Urine was obtained from three healthy volunteers, ages 25–40. The samples were dialyzed overnight against 2.5 mm Tris, pH 7.5, then lyophilized and resuspended in water in order to achieve a 30-fold concentration prior to ELISA assay.

**Cell Cultures**—All cells were grown at 37 °C in 75-cm² flasks containing 2 ml of MEM (Gibco modified Eagle’s medium-high glucose + glutamine with 0.08 M Hepes buffer (pH 7.6), 20% fetal calf serum, and 200 units of penicillin and 200 µg of streptomycin/mL. At visual confluence, the cells were placed in serum-free medium for 24 h. The medium was harvested and stored at −20 °C.

Normal human skin fibroblasts were purchased from the American Type Culture Collection. Human corneal fibroblasts were obtained from J. Gordon, Washington University School of Medicine, and adult human lung fibroblasts were kindly provided by J. Clark, Washington University School of Medicine. Human uterine smooth muscle cells were obtained from J. Jeffrey, Washington University School of Medicine. Fibroblasts, from a human fibrosarcoma were cultured following surgical excision of the tumor. Serum-free medium containing 10 ml of Dulbecco’s modified Eagle’s medium-high glucose was utilized to measure immunoreactive protein by the ELISA method.

**Collagenase Inhibitor Assay**—Human skin fibroblast collagenase inhibitor purified to homogeneity from monolayer cultures of normal human skin fibroblasts (27). Serum-free medium from adult and fetal lung fibroblasts, gingival fibroblasts, normal fibroblasts, fetal osteoblasts, and fibrosarcoma cells was dialyzed overnight against 0.1 M acetic acid, lyophilized, resuspended in 0.05 M Tris, pH 7.5, to achieve a 10-fold concentration, and then centrifuged at 10,000 X g for 10 min. This concentrated medium, now free of any intrinsic collagenase activity, was used to test for functional inhibitory capacity and in Ouchterlony gel diffusion; unconcentrated medium was utilized to measure immunoreactive protein by the ELISA method. In the case of serum-free medium from tendon and cartilage explants, and amniotic fluid, a different method for concentration was employed because dialysis against acetic acid resulted in significant precipitation. These samples were instead dialyzed against 5 mm Tris, 10 mm EDTA, pH 7.5, then dialyzed three times against 5 mm Tris, pH 7.5, lyophilized to obtain 10-fold concentration, and then resuspended in water.

**Collagenase Inhibitor Assay**—Human skin fibroblast collagenase was purified to homogeneity as described previously (25, 26). The enzyme was adsorbed on preformed goat anti-human collagen type I IgG-Sepharose 4B, eluted with 100 mM glycine buffer, pH 2.5, lyophilized, resuspended in water.

**RESULTS**

An enzyme-linked immunosorbent assay for human skin fibroblast collagenase inhibitor was developed using antigen purified to homogeneity and a functionally specific rabbit anti-inhibitor antibody. In order to test inhibitor binding to the plates and antigen-antibody interaction, polystyrene microtiter plates were coated with serial dilutions of inhibitor antigen and then incubated with serial dilutions of inhibitor-specific antibody. Goat anti-rabbit IgG conjugated to alkaline phosphatase was added, followed by incubation with substrate. A family of curves was thereby established, as shown in Fig. 1. In order to utilize the assay for measuring antigen, indirect inhibition ELISA methodology (32) was employed. Test solutions of either known amounts of pure inhibitor or various unknowns were pre-incubated with the specific antisera prior to its addition to the wells which contained antigen coated to their surface. Using this tech-
The combination of coating antigen and rabbit inhibitor-specific antibody which resulted in the highest degree of identity against pure inhibitor protein in Ouchterlony gel. Furthermore, all samples displayed an immunologic reaction in conditions, a typical standard curve for the measurement of human skin fibroblast collagenase inhibitor was produced as shown in Fig. 2. The minimum sensitivity for the ELISA was 10 ng/ml, or 2 ng of inhibitor protein.

Several experiments were performed to assess the correlation of immunoreactive material as measured by ELISA with functional inhibitor activity and also to evaluate the accuracy and precision of the assay. Serum-free medium from four replicate culture flasks of a single human skin fibroblast line was examined for both immunoreactive inhibitor protein and functional collagenase inhibitory capacity. Table IA shows the correlation between the two, as measured by inhibitor activity per immunoreactive protein. The variation around the mean of approximately 20% was expected because of the inherent errors of the ELISA and functional assays combined, and the error involved in concentrating the medium protein for the latter assay. To test the accuracy of the ELISA, known chemical quantities of human skin fibroblast collagenase inhibitor were measured by this method. Despite widely varying inhibitor concentrations, the ELISA determinations were accurate to within 10% (Table IB). Precision or reproducibility was examined by using the same aliquoted sample of inhibitor in three ELISA assays performed on three different days. All measurements were within 10% of the mean (data not shown).

In order to perform comparative studies, immunoreactive material was measured in cell and explant culture media from a variety of human connective tissues. Serum-free media from confluent monolayer cultures of corneal, adult and fetal lung, and gingival fibroblasts all contained immunoreactive inhibitor protein in concentrations similar to the levels found in human skin fibroblast cultures (Table II). When tested for functional inhibitory activity, an approximate 1:1 stoichiometry of collagenase inhibition per immunoreactive protein was observed, just as for the skin fibroblasts (Tables IB and II). Furthermore, all samples displayed an immunologic reaction of identity against pure inhibitor protein in Ouchterlony gel diffusion (Fig. 3). Similar results were obtained for tumor cells grown in monolayer culture from a human fibrosarcoma (Table II and Fig. 3). Serum-free medium from confluent monolayer cultures of human fetal osteoblasts likewise contained easily measurable quantities of immunoreactive inhibitor protein by ELISA. Functional collagenase inhibitory activity per immunoreactive material was the same as for the skin fibroblast inhibitor, and a line of immunologic identity was also observed in Ouchterlony analysis (Table II and Fig. 3). Confluent monolayer cultures of human uterine smooth muscle cells produced significant amounts of immunoreactive material only in the presence of serum-containing medium.
Comparative Studies of Human Skin Collagenase Inhibitor

Immunoreactive inhibitor protein in cell and explant cultures of human tissues

Immunoreactive protein in confluent cell culture or explant medium was measured by ELISA assay following incubation for 24-48 h under serum-free conditions.

| Inhibitor source | Immunoreactive protein in culture medium | Inhibitory activity/immunoreactive protein
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cells</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin fibroblasts</td>
<td>1.3</td>
<td>1.0</td>
</tr>
<tr>
<td>Corneal fibroblasts</td>
<td>1.2</td>
<td>1.1</td>
</tr>
<tr>
<td>Lung fibroblasts</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adult</td>
<td>3.1</td>
<td>1.2</td>
</tr>
<tr>
<td>Fetal</td>
<td>3.0</td>
<td>0.9</td>
</tr>
<tr>
<td>Gingival fibroblasts</td>
<td>0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>Fibrosarcoma</td>
<td>1.0</td>
<td>0.9</td>
</tr>
<tr>
<td>Uterus smooth muscle</td>
<td>0.6^a, 0.05^c</td>
<td>0.9</td>
</tr>
<tr>
<td>Fetal osteoblasts</td>
<td>0.25</td>
<td>0.8</td>
</tr>
<tr>
<td>Keratinocytes</td>
<td>0.03^a, 0.03^c</td>
<td>—</td>
</tr>
<tr>
<td>Explants</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tendon</td>
<td>1.5</td>
<td>0.7</td>
</tr>
<tr>
<td>Articular cartilage</td>
<td>1.1</td>
<td>1.0</td>
</tr>
<tr>
<td>Skin</td>
<td>0.11</td>
<td>—</td>
</tr>
</tbody>
</table>

^a Molecules of collagenase inhibited/molecule of immunoreactive inhibitor protein.
^b Immunoreactive protein in confluent cell cultures containing 10% fetal calf serum.
^c Immunoreactive protein in confluent cell cultures cycled for 24-48 h in serum-free medium.
^d —, not performed due to insufficient quantities of inhibitor present in serum-free medium.

The presence of immunoreactive inhibitor protein was also examined in several human body fluids (Table III). As shown in the preceding paper (27), human serum contains a β-globulin collagenase inhibitor that behaves identically to skin fibroblast inhibitor when subjected to several of the chromatographic procedures used to purify the latter (27). When a sample of serum partially purified in this manner was studied in Ouchterlony gel diffusion, an immunologic line of identity with human skin fibroblast collagenase inhibitor could readily be discerned (Fig. 3). Additionally, when functional collagenase inhibitory activity was examined in this sample, which was free of any α2-macroglobulin, the stoichiometry of collagenase inhibition per immunoreactive material was 1:1 (Table III). The amount of immunoreactive inhibitor protein present in the sera of seven healthy individuals was measured by ELISA and is shown in Table III. Normal human serum contains approximately 1 μg/ml of this material with a standard deviation of 25% around the mean. Apparently, very little of this protein is excreted by the kidney, since its concentration in urine was <0.02 μg/ml in all cases.

| Body fluid and sample number | Immunoreactive protein | Inhibitory activity/immunoreactive protein
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>0.86</td>
<td>0.8</td>
</tr>
<tr>
<td>1</td>
<td>1.08</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>1.05</td>
<td>1.0</td>
</tr>
<tr>
<td>3</td>
<td>1.57</td>
<td>1.0</td>
</tr>
<tr>
<td>4</td>
<td>1.10</td>
<td>1.0</td>
</tr>
<tr>
<td>5</td>
<td>0.81</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>0.74</td>
<td>1.0</td>
</tr>
<tr>
<td>Mean ± S.D.</td>
<td>1.03 ± 0.27</td>
<td>0.9</td>
</tr>
<tr>
<td>Amniotic fluid</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4.91</td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>2.29</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>5.10</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>3.21</td>
<td></td>
</tr>
<tr>
<td>Mean ± S.D.</td>
<td>3.88 ± 1.36</td>
<td>1.1</td>
</tr>
<tr>
<td>Urine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-3</td>
<td>&lt;0.02</td>
<td></td>
</tr>
</tbody>
</table>

* Molecules of collagenase inhibited/molecule of immunoreactive inhibitor protein.
Amniotic fluid was obtained from four patients undergoing amniocentesis at ≥36 weeks of gestation to assess fetal lung maturity prior to cesarean section. Considerably higher levels of immunoreactive inhibitor protein as compared to serum values were measured by ELISA (3.88 ± 1.36 versus 1.03 ± 0.27 μg/ml). When amniotic fluid was concentrated and studied by Ouchterlony gel diffusion, an immunologic reaction of identity could be observed against the pure fibroblast inhibitor (Fig. 9). Since α2-macroglobulin, the major collagenase inhibitor in serum, is too large to gain access into the amniotic fluid in significant amounts (33, 34), the latter was examined for functional collagenase inhibitory activity without prior chromatographic separation. The stoichiometry of collagenase inhibition produced per immunoreactive inhibitor protein was 1.1 to 1.0.

**Discussion**

Human skin fibroblasts in monolayer culture secrete a collagenase inhibitor of $M_r = 28,500$ that stoichiometrically inhibits collagenase activity on a 1:1 molar basis (10, 27). The production of this or other immunologically similar inhibitor proteins in human connective tissues and their presence in human body fluids were studied using pure antigen, a functionally specific antibody, and an enzyme-linked immunosorbent assay. The ELISA can measure human skin fibroblast collagenase inhibitor in an accurate and precise manner, and can detect as little as 2 ng of inhibitor protein (Fig. 2).

Monolayer fibroblast cultures from human cornea, lung, and gingiva all secreted immunoreactive inhibitor protein into serum-free medium at levels between 0.8 and 3.1 μg/ml. Following dialysis in acetic acid or EDTA to destroy any intrinsic collagenase, each fibroblast-derived medium inhibited fibrillar collagenolysis in a stoichiometric manner with respect to subsequently added enzyme, based upon the amount of immunoreactive material measured by ELISA. Thus, functional activity and immunoreactive inhibitor protein showed the same correlation in these fibroblast cultures that was observed for the skin fibroblasts. Furthermore, concentrated medium from all fibroblast lines reacted with immunologic identity against pure human skin fibroblast collagenase inhibitor in Ouchterlony gel diffusion. It would therefore seem apparent that fibroblasts from many human connective tissues produce a collagenase inhibitor that is functionally equivalent to and immunologically identical, and most probably structurally identical, with the inhibitor produced by human skin fibroblasts. Cells from a malignant tumor of connective tissue, a fibrosarcoma, likewise secreted such a collagenase inhibitor. Production of the inhibitor was also evidenced in fetal tissues, as shown by its presence in the medium of fetal lung fibroblasts which was indistinguishable from that found in cultures of adult lung fibroblasts.

Mesodermally derived cell types other than fibroblasts also secrete such a collagenase inhibitory protein. Human smooth muscle cells and human fetal osteoblasts in monolayer culture produced slightly less immunoreactive inhibitor protein than fibroblasts as measured by ELISA; both displayed an immunologic line of identity with human skin fibroblast collagenase inhibitor when tested in Ouchterlony gel diffusion. While explant cultures of human articular cartilage probably contain a heterogeneous population of cells, the level of immunoreactive protein elaborated at least suggests that the inhibitor is produced by the predominant cell type present, the chondrocyte. The inhibitor protein secreted by cartilage explants is also identical with human skin fibroblast collagenase inhibitor with respect to functional activity and immunologic reactivity as assessed by Ouchterlony analysis. On the other hand, monolayer cultures of an epithelium-derived cell type, the human keratinocyte, produced <5% of the immunoreactive protein synthesized by the fibroblast cultures. It cannot be determined at the present time whether this amount of immunoreactive material represents an extremely low level of inhibitor production by these epithelial cells or trace contamination of low-passage cultures with dermal fibroblasts.

All human skin fibroblast lines examined to date secrete detectable amounts of inhibitor when separated from the simultaneously produced procollagenase by chromatographic techniques, and then assayed for functional inhibitory activity. In contrast, explants of human skin in culture have usually failed to yield significant levels of such an inhibitor (10). When human skin explant culture medium was subjected to ELISA assay, the concentration of inhibitor was found to be only 10% of that generally present in the medium of monolayer fibroblast cell cultures. Such quantities would not be readily detectable by functional assay and probably explain the difficulty in previously identifying this protein in skin explant culture medium. The reason for these low levels of inhibitor may be related to the observation that such explants undergo massive collagen resorption in culture (35). It is possible that, under these conditions, regulatory mechanisms would reduce inhibitor production. Since anti-inhibitor antibody reacts equally well with free inhibitor or inhibitor bound to enzyme (data not shown), the presence of active collagenase in such explants would not help to explain the diminished immunoreactive inhibitor levels.

Human serum is a potent inhibitor of mammalian collagenase action (6). Greater than 95% of the collagenase inhibitory capacity of serum has been shown to reside in the general antiprotease, α2-macroglobulin (7). The remaining few per cent has been attributed to a 40,000-Da β1-globulin which acts as a specific inhibitor of mammalian collagenase, and has been designated as β1-anticollagenase (7, 16). As shown in the preceding paper (27), pure human skin fibroblast collagenase inhibitor also migrates in the β-position on immunoelectrophoresis. Furthermore, when human serum was subjected to several of the chromatographic procedures employed for the purification of the fibroblast inhibitor, a serum anticollagenase was identified which behaved in a manner identical with the fibroblast-derived inhibitor (27). Ouchterlony gel diffusion of human serum partially purified by such techniques revealed a line of immunologic identity with the skin fibroblast collagenase inhibitor (Fig. 3); stoichiometry of collagenase inhibition was also identical with the fibroblast protein (Table III). It is therefore possible that human fibroblast inhibitor and β1-anticollagenase represent the same protein. The concentration of this inhibitor, as measured in the serum of seven healthy volunteers by ELISA, is 1.03 ± 0.27 μg/ml. Assuming an approximate concentration for α2-macroglobulin in serum of 2 mg/ml (36), and accounting for differences in molecular weight, human fibroblast inhibitor would be expected to contribute 1-2% of the collagenase inhibitory activity found in serum. It would seem likely that, due to its $M_r$ of ~30,000 and its presence in connective tissues throughout the body, the inhibitor may gain access into the bloodstream from capillaries which bathe the extracellular space of such tissues. However, little of the serum inhibitor is filtered through the renal glomeruli and excreted in the urine (Table III).

A collagenase inhibitor has been reported in human amniotic fluid which has properties similar to human skin fibroblast collagenase inhibitor with respect to molecular weight, carbohydrate content, and thermal stability (17, 18). When four amniotic fluid specimens were tested by ELISA assay, they were found to contain an average of 3-4 μg/ml of im-

Downloaded from http://www.jbc.org/ by guest on October 16, 2017
munoreactive protein. Concentrated amniotic fluid displayed stoichiometric inhibition of collagenase activity, in addition to an immunologic reaction of identity with pure skin fibroblast inhibitor in Ouchterlony gel diffusion. These data, thus, also suggest that the collagenase inhibitor in human amniotic fluid is the same as or a closely related protein to human fibroblast collagenase inhibitor. Since the large majority of proteins found in amniotic fluid originate from maternal serum (33), the latter may be the source of the inhibitor which is contained in such fluid, although a fetal source cannot be excluded at this time.

The results of this study suggest that a similar, if not identical, collagenase inhibitor is produced by human skin fibroblasts, corneal fibroblasts, gingival fibroblasts, adult and fetal lung fibroblasts, uterine smooth muscle cells, fetal osteoblasts, tendon, and cartilage explants. Furthermore, this protein is found in certain body fluids, such as serum and amniotic fluid. Although the inhibitor proteins from all these sources share the same functional activity and an identical immunologic behavior, further studies will be required to assess the exact extent of structural similarity in each case. Nevertheless, the data do suggest that such a collagenase inhibitor is produced by most, if not all, fetal and adult mesodermal tissues in the human organism, and by at least one mesodermally derived malignant tumor. This inhibitor protein may therefore serve to regulate collagenase activity during normal and abnormal collagen turnover in many connective tissues throughout the body.

Acknowledgments—We thank Nadean Brown, Kitty Fliszar, and Sharon Favors for their excellent technical assistance. We also thank Drs. Eugene Bauer, John Jeffrey, and Arthur Eisen for helpful discussions.

REFERENCES

Human skin fibroblast collagenase inhibitor. Comparative studies in human connective tissues, serum, and amniotic fluid.
H G Welgus and G P Stricklin


Access the most updated version of this article at http://www.jbc.org/content/258/20/12259

Alerts:
  • When this article is cited
  • When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 0 references, 0 of which can be accessed free at http://www.jbc.org/content/258/20/12259.full.html#ref-list-1